Did Sapropterin Eliminate Symptoms Completely for All Patients?
No, sapropterin (Kuvan) did not eliminate symptoms completely for all patients with phenylketonuria (PKU). Clinical trials showed it reduced blood phenylalanine (Phe) levels in only about 20-50% of patients, depending on the study and dose, with responders defined as those achieving at least 30% reduction. Non-responders—often half or more—saw no meaningful change, requiring them to continue a Phe-restricted diet.[1][2]
How Was Responsiveness Measured in Trials?
In the Phase 3 PKU-004 trial, 261 adults and children received 20 mg/kg/day sapropterin for 6 weeks. Only 56% (146 patients) were responders, with average Phe drops of 34-57%. Complete symptom elimination wasn't a trial endpoint; the focus was Phe control, as untreated PKU causes irreversible cognitive damage from high Phe. Long-term open-label extensions confirmed sustained response in most initial responders but no universal cure.[1][3]
What Symptoms Persist Even in Responders?
Responders often still need some dietary restriction and monitoring. Sapropterin enhances phenylalanine hydroxylase activity to metabolize Phe naturally, but it doesn't restore full enzyme function. Residual symptoms like mild neurocognitive issues or growth delays can linger if Phe isn't normalized perfectly. Complete elimination would require 100% Phe normalization in everyone, which trials didn't achieve.[2][4]
Why Don't All Patients Respond?
Variability stems from PKU mutations—over 1,000 types exist, and sapropterin works best on BH4-responsive ones (e.g., certain PAH gene variants). Testing via a 24-48 hour challenge identifies responders. Non-responders lack sufficient residual enzyme activity. Age, baseline Phe, and adherence also factor in; infants respond better than adults.[3][5]
What Happens to Non-Responders?
They revert to strict low-Phe diets, formula supplements, or emerging therapies like pegvaliase (Palynziq), an enzyme substitute approved in 2018 for adults. Sapropterin isn't a standalone fix; guidelines recommend it only for confirmed responders alongside diet.[4][6]
Trial Data on Long-Term Outcomes
In a 10-year extension study of 341 patients, 84% of initial responders maintained Phe control, but dropout rates were high (only 57% completed). No data showed total symptom reversal across the board; quality-of-life gains were partial, tied to Phe reduction.[3]
[1]: FDA Label for Kuvan (sapropterin)
[2]: NEJM: Phase 3 Trial Results (2007)
[3]: Molecular Genetics and Metabolism: Long-term Extension (2018)
[4]: ACMG Practice Guidelines for PKU (2014)
[5]: JIMD Reports: BH4 Responsiveness Testing
[6]: BioMarin Patient Site on PKU Treatments